Marija Zecevic Ph.D. serves as Chief Operating Officer of the Company. Dr. Zecevic has been serving as our Chief Commercial Officer since February 2019, and previously served as our Chief Operating Officer from February 2018 to February 2019. Previously, Dr. Zecevic served as our Chief Business Officer from March 2017 to February 2018 and Vice President of Business Development from August 2016 to March 2017. From April 2009 to July 2016, she served as Founder and Managing Director of Zebra Ventures Srl., which firm provided business development consulting services for Proteostasis from August 2014 to July 2016. During her tenure as the Managing Director, she also served as the Founder and Coordinator of the Industry Liaison Office of the Italian Cystic Fibrosis Foundation and as the Acting Head of Business Development of Allozyne Inc. Prior to joining Zebra Ventures Srl., Dr. Zecevic served as the Business Development Manager of BioXell SpA (SWX: BXLN) from October 2005 to March 2009 and as Staff Scientist from March 2003 to September 2005. Dr. Zecevic received a B.S. in Molecular Biology from the University of Belgrade in Serbia, a Ph.D. in Biochemistry from the Institute of Physiology at the University of Zurich, Switzerland, and a Masters in International Healthcare Management, from the Bocconi School of Management in Milan, Italy.
As the Chief Operating Officer of Proteostasis Therapeutics Inc, the total compensation of Marija Zecevic at Proteostasis Therapeutics Inc is $955,307. There are 1 executives at Proteostasis Therapeutics Inc getting paid more, with Meenu Chhabra having the highest compensation of $1,980,720.
Marija Zecevic is 47, she's been the Chief Operating Officer of Proteostasis Therapeutics Inc since 2019. There are 8 older and no younger executives at Proteostasis Therapeutics Inc. The oldest executive at Proteostasis Therapeutics Inc is Franklin Berger, 70, who is the Independent Chairman of the Board.
Marija's mailing address filed with the SEC is C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON, MA, 02135.
Over the last 9 years, insiders at Proteostasis Therapeutics Inc have traded over $9,140,918 worth of Proteostasis Therapeutics Inc stock and bought 12,301,024 units worth $94,383,855 . The most active insiders traders include M James Barrett, Llc Fmr, and Bioventures Ltd Novartis Ag.... On average, Proteostasis Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $3,463,082. The most recent stock trade was executed by Enterprise Associates 12, L... on 26 November 2019, trading 1,283,919 units of PTI stock currently worth $3,222,637.
Proteostasis Therapeutics Inc executives and other stock owners filed with the SEC include: